Apogee Therapeutics (APGE) Gains from Investment Securities (2022 - 2026)
Apogee Therapeutics (APGE) reported Gains from Investment Securities of -$155000.0 for Q1 2026, down 115.52% year-over-year from $999000.0 in Q1 2025, and down 119.11% quarter-over-quarter from $810997.0 in Q3 2025.
Apogee Therapeutics (APGE) Gains from Investment Securities (2022 - 2026) Analysis & Trends
Apogee Therapeutics (APGE) has 5 years of Gains from Investment Securities data on file, last reported at -$155000.0 in Q1 2026.
- Gains from Investment Securities for Q1 2026 came in at -$155000.0, down 115.52% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.0 million (changed N/A YoY), and the FY2025 annual result was $5.6 million, up 8.83% from the prior year.
- Gains from Investment Securities slipped to -$155000.0 in Q1 2026 per APGE's latest filing, from $810997.0 in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $4.6 million in Q2 2023 and troughed at -$155000.0 in Q1 2026.
- A 5-year average of $1.3 million and a median of $904998.5 in 2025 frame the typical range for Gains from Investment Securities.
- The sharpest annual moves came in 2025 and 2026: Gains from Investment Securities jumped 2265.53% in 2025, then tumbled 115.52% in 2026.
- A 5-year view of Gains from Investment Securities shows it stood at $2.8 million in 2022, then fell by 9.34% to $2.5 million in 2023, then sank by 52.63% to $1.2 million in 2024, then tumbled by 31.68% to $810997.0 in 2025, then slumped by 119.11% to -$155000.0 in 2026.
- Business Quant data shows APGE's Gains from Investment Securities at -$155000.0 in Q1 2026, $810997.0 in Q3 2025, and $77208.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Apogee Therapeutics | 6.29 Bn | 5.23 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -155,000.00 |
| Mar 31, 2026 | -155,000.00 |
| Sep 30, 2025 | 810,997.00 |
| Sep 30, 2025 | 810,997.00 |
| Jun 30, 2025 | 77,208.00 |
| Jun 30, 2025 | 77,208.00 |
| Mar 31, 2025 | 999,000.00 |
| Mar 31, 2025 | 999,000.00 |
| Dec 31, 2024 | 1.19 Mn |
| Dec 31, 2024 | 1.19 Mn |
| Sep 30, 2024 | 34,284.00 |
| Sep 30, 2024 | 34,284.00 |
| Jun 30, 2024 | 18,461.00 |
| Jun 30, 2024 | 18,461.00 |
| Mar 31, 2024 | 2.62 Mn |
| Mar 31, 2024 | 2.62 Mn |
| Dec 31, 2023 | 2.51 Mn |
| Dec 31, 2023 | 2.51 Mn |
| Sep 30, 2023 | 637,546.00 |
| Sep 30, 2023 | 637,546.00 |